King Luther Capital Management Corp Lowers Holdings in Agilent Technologies, Inc. (NYSE:A)

King Luther Capital Management Corp reduced its position in shares of Agilent Technologies, Inc. (NYSE:A) by 30.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,116 shares of the medical research company’s stock after selling 5,742 shares during the quarter. King Luther Capital Management Corp’s holdings in Agilent Technologies were worth $1,700,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies during the fourth quarter valued at approximately $26,000. Crewe Advisors LLC boosted its position in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Ridgewood Investments LLC bought a new position in Agilent Technologies in the second quarter worth about $29,000. Rise Advisors LLC boosted its holdings in shares of Agilent Technologies by 527.8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after buying an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. purchased a new position in shares of Agilent Technologies in the 1st quarter worth approximately $34,000. 87.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A has been the subject of several recent analyst reports. Barclays raised their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research note on Friday, August 23rd. Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research note on Monday, August 26th. UBS Group raised their price target on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. cut their price objective on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Finally, Bank of America lifted their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $141.60.

Agilent Technologies Stock Down 1.3 %

Shares of A stock opened at $140.09 on Friday. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $155.35. The stock has a market cap of $40.87 billion, a P/E ratio of 33.12, a P/E/G ratio of 6.43 and a beta of 1.05. The stock has a 50 day moving average of $137.87 and a 200 day moving average of $139.21. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period in the previous year, the firm earned $1.43 EPS. The business’s quarterly revenue was down 5.6% on a year-over-year basis. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st will be given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.